Anti-Human FGFR-1 (IIIb)-Anti-Human FGFR-1 (IIIb)代理/參數(shù)/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產(chǎn)品中心

當(dāng)前位置：首頁 > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > 一抗

中文名稱: Anti-Human FGFR-1 (IIIb)

英文名字: Anti-Human FGFR-1 (IIIb)

供應(yīng)商: ReliaTech

產(chǎn)品貨號: 101-M415

產(chǎn)品報價: ￥詢價/100ug

產(chǎn)品說明書: 點擊查看

購買方式: 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

產(chǎn)品新聞

背景資料: Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorgenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1-4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig) like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1-3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the α isoform, or only IgII and IgIII, referred to as the β isoform. Only the α isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1-3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF- -R1. Mutations in FGF R1-3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members is an important research topic.

應(yīng)用類型: WB

免疫原: 該Anti-Human FGFR-1 (IIIb)的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

來源宿主: 該Anti-Human FGFR-1 (IIIb)的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

反應(yīng)性: 該Anti-Human FGFR-1 (IIIb)的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

保存建議: 該Anti-Human FGFR-1 (IIIb)的詳細信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.

其他: ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。